Literature DB >> 30098724

The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond.

Halfdan Sorbye1, Eric Baudin2, Aurel Perren3.   

Abstract

High-grade gastroenteropancreatic neuroendocrine neoplasms are well-differentiated neuroendocrine tumors or poorly differentiated small/large cell neuroendocrine carcinoma. Distinguishing these entities relies on different genetic backgrounds and resulting different biology. The new classification creates several problems. Almost all clinical treatment data on neuroendocrine neoplasms do not stratify between well and poorly differentiated, providing insufficient help in treatment selection. Treatment of gastroenteropancreatic neuroendocrine neoplasms should separate between well-differentiated neuroendocrine tumors and neuroendocrine carcinoma, and depends on primary tumor site, stage, proliferation rate, and clinical course. This article addresses how to diagnose and treat gastroenteropancreatic neuroendocrine neoplasms, focusing on well-differentiated neuroendocrine tumors versus neuroendocrine carcinomas.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinoma; Digestive; Gastroenteropancreatic; NEC; NET G3; Neoplasms; Neuroendocrine

Mesh:

Year:  2018        PMID: 30098724     DOI: 10.1016/j.ecl.2018.05.001

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  21 in total

Review 1.  Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.

Authors:  Mohamad Bassam Sonbol; Thorvardur R Halfdanarson
Journal:  Curr Treat Options Oncol       Date:  2019-08-19

2.  Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Chiara Liverani; Alberto Bongiovanni; Laura Mercatali; Federica Pieri; Chiara Spadazzi; Giacomo Miserocchi; Giandomenico Di Menna; Flavia Foca; Sara Ravaioli; Alessandro De Vita; Claudia Cocchi; Giulio Rossi; Federica Recine; Toni Ibrahim
Journal:  Endocr Pathol       Date:  2021-01-06       Impact factor: 3.943

3.  Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.

Authors:  Alex J Liu; Benjamin E Ueberroth; Patrick W McGarrah; Skye A Buckner Petty; Ayse Tuba Kendi; Jason Starr; Timothy J Hobday; Thorvardur R Halfdanarson; Mohamad Bassam Sonbol
Journal:  Oncologist       Date:  2021-02-08

4.  Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-analysis.

Authors:  Ioannis A Ziogas; Panagiotis T Tasoudis; Luis C Borbon; Scott K Sherman; Patrick J Breheny; Chandrikha Chandrasekharan; Joseph S Dillon; Andrew M Bellizzi; James R Howe
Journal:  Ann Surg Oncol       Date:  2022-10-13       Impact factor: 4.339

5.  Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors.

Authors:  Baicheng Li; Xinjun Li; Ruiqi Mao; Min Liu; Limei Fu; Lifang Shi; Songlin Zhao; Mingxia Fu
Journal:  Endocr Pathol       Date:  2020-09-01       Impact factor: 3.943

Review 6.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

7.  Value of computed tomography evaluation in pathologic classification and prognosis prediction of gastric neuroendocrine tumors.

Authors:  Shida Yan; Tongtong Liu; Ying Li; Yongjian Zhu; Jun Jiang; Liming Jiang; Hong Zhao
Journal:  Ann Transl Med       Date:  2019-10

8.  Development and Validation of Novel Nomograms Using Serum Tumor Markers for the Prediction of Preoperative Histologic Grades in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Yan Li; Zhi-Qi Wu; Qin Xu; Hemant Goyal; Hua-Guo Xu
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

Review 9.  Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions.

Authors:  Anna Pellat; Anne Ségolène Cottereau; Lola-Jade Palmieri; Philippe Soyer; Ugo Marchese; Catherine Brezault; Romain Coriat
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

10.  Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma.

Authors:  Patrick W McGarrah; Konstantinos Leventakos; Timothy J Hobday; Julian R Molina; Heidi D Finnes; Gustavo F Westin; Thorvardur R Halfdanarson
Journal:  Pancreas       Date:  2020-04       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.